Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into its first concierge medicine contract with LEAA Health. The contract provides LEEA Health’s membership-based patients access to groundbreaking esophageal precancer testing using Lucid’s EsoGuard® Esophageal DNA Test. This expands LEAA Health’s enhanced personalized care services, which it offers to its patients on a cash-pay basis. Lucid aims to drive contractually-guaranteed revenue by capitalizing on the growing demand for prevention-focused healthcare services in the expanding concierge medicine market.
“We are thrilled to enter into our first concierge medicine contract with LEAA Health to expand access to EsoGuard precancer testing,” said Shaun O’Neil, Lucid’s President and Chief Operating Officer. “We have committed to growing contractually-guaranteed EsoGuard revenue in parallel with our intensive efforts to secure Medicare and commercial coverage. Our recently launched cash-pay program targeting concierge medicine is an important component of this strategic initiative. Concierge medicine patients actively seek innovative preventive care solutions such as EsoGuard and we are pleased to offer our solution as part of LEAA Health’s enhanced personalized care offerings.”
“This partnership with Lucid aligns perfectly with LEAA Health’s mission to provide top-tier, personalized healthcare solutions to our patients,” said Isaak N. Yakubov, Founder and CEO of LEAA Health. “EsoGuard represents a groundbreaking approach to esophageal precancer detection, allowing us to identify potential issues at an early stage when intervention can be most effective. By offering EsoGuard as a screening tool to all eligible patients, we are expanding access to this innovative test and enhancing our ability to deliver proactive, personalized care that could potentially save lives.”
The 2024 Annual Report from Concierge Medicine Today indicates that the concierge medicine market in the United States is projected to reach $10.9 billion by 2032, reflecting the increasing demand for personalized, prevention-focused healthcare services.
